Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats

被引:119
作者
Heiberg, IL
Wegener, G
Rosenberg, R
机构
[1] Inst Basic Psychiat Res, Dept Biol Psychiat, DK-8240 Risskov, Denmark
[2] Aarhus Univ, Ctr Clin Pharmacol, DK-8000 Aarhus C, Denmark
关键词
forced swimming test; animal behaviour; depression; cGMP; nitric oxide; 1H-[1,2,4]oxadiazole[4,3-a]quinoxatin-1-one; 7-nitroindazole;
D O I
10.1016/S0166-4328(02)00084-0
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The forced swimming test (FST) has been extensively used as a screening model for new antidepressant agents. It has been shown that drugs which reduce the amount or nitric oxide (NO) have the same outcome in this model as classic antidepressants. In addition, previous studies have shown that methylene blue, which acts as a direct inhibitor of both NOS and soluble guanylate cyclase (sGC), mimics the effect of clinically effective antidepressants in patients and in the FST. The present study examined the effects of the specific inhibitor of the NO-sGC pathway, [1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-one] (ODQ) and of the neuronal NOS inhibitor 7-nitroindazole (7-NI) in the FST. We found that ODQ (10 and 20 mg/kg) significantly decreased the immobility time in the FST compared to the control. Similarly, injections of 7-NI (30 or 60 mg/kg) reduced immobility time as well as Imipramine (IMI, 30 mg/kg). Interestingly, L-Arginine (250 mg/kg) administered in combination with ODQ reversed the effect of ODQ but displayed no effect when administered alone. Locomotion activity was significantly decreased following administration of IMI (30 mg/kg) and 7-NI (30 and 60 mg/kg) but was unaffected after administration of ODQ (10 and 20 mg/kg). These findings suggest that the NO-sGC-cGMP pathway may play an important role in the mediation of the behavioural effect in the FST without influence on motor activity. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:479 / 484
页数:6
相关论文
共 47 条
[1]   Atypical neural messengers [J].
Barañano, DE ;
Ferris, CD ;
Snyder, SH .
TRENDS IN NEUROSCIENCES, 2001, 24 (02) :99-106
[2]   Characterization of ionotropic glutamate receptor-mediated nitric oxide production in vivo in rats [J].
Bhardwaj, A ;
Northington, FJ ;
Ichord, RN ;
Hanley, DF ;
Traystman, RJ ;
Koehler, RC .
STROKE, 1997, 28 (04) :850-856
[3]   BEHAVIORAL-EFFECTS OF VEHICLES - DMSO, ETHANOL, TWEEN-20, TWEEN-80, AND EMULPHOR-620 [J].
CASTRO, CA ;
HOGAN, JB ;
BENSON, KA ;
SHEHATA, CW ;
LANDAUER, MR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1995, 50 (04) :521-526
[4]  
Dawson T M, 1995, New Horiz, V3, P85
[5]  
Dawson TM, 1998, PROG BRAIN RES, V118, P3
[6]   Guanylate cyclase and the .NO/cGMP signaling pathway [J].
Denninger, JW ;
Marletta, MA .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 1999, 1411 (2-3) :334-350
[7]   New and potent inhibitors of nitric oxide synthase reduce motor activity in mice [J].
Dzoljic, E ;
DeVries, R ;
Dzoljic, MR .
BEHAVIOURAL BRAIN RESEARCH, 1997, 87 (02) :209-212
[8]   Anxiolytic and antidepressant properties of methylene blue in animal models [J].
Eroglu, L ;
Caglayan, B .
PHARMACOLOGICAL RESEARCH, 1997, 36 (05) :381-385
[9]   The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a]quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation [J].
Feelisch, M ;
Kotsonis, P ;
Siebe, J ;
Clement, B ;
Schmidt, HHHW .
MOLECULAR PHARMACOLOGY, 1999, 56 (02) :243-253
[10]   ENDOTHELIUM-DERIVED RELAXING FACTOR RELEASE ON ACTIVATION OF NMDA RECEPTORS SUGGESTS ROLE AS INTERCELLULAR MESSENGER IN THE BRAIN [J].
GARTHWAITE, J ;
CHARLES, SL ;
CHESSWILLIAMS, R .
NATURE, 1988, 336 (6197) :385-388